NASDAQ:SRZN Surrozen Q1 2025 Earnings Report $8.40 -0.01 (-0.12%) Closing price 04:00 PM EasternExtended Trading$8.46 +0.05 (+0.65%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Surrozen EPS ResultsActual EPS-$3.13Consensus EPS -$1.09Beat/MissMissed by -$2.04One Year Ago EPSN/ASurrozen Revenue ResultsActual Revenue$0.98 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASurrozen Announcement DetailsQuarterQ1 2025Date5/9/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time12:30PM ETUpcoming EarningsSurrozen's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Surrozen Earnings HeadlinesWe Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthJuly 1, 2025 | finance.yahoo.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.com[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to two crypto experts, that moment is here. Their Crypto Code Workshop shows how to get positioned before altcoins take off, ride the wave, and lock in gains — with a free $10 Bitcoin bonus just for attending.July 16 at 2:00 AM | Crypto Swap Profits (Ad)Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSurrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comSee More Surrozen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email. Email Address About SurrozenSurrozen (NASDAQ:SRZN) (NASDAQ: SRZN) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibodies that modulate the Wnt signaling pathway. Founded in 2013 and headquartered in South San Francisco, California, the company leverages its proprietary platform to advance regenerative medicine programs aimed at addressing diseases with high unmet medical need. The company’s lead programs target tissue repair and regeneration in areas such as ophthalmology and liver disease. Surrozen’s pipeline includes antibody candidates designed to selectively activate Wnt co-receptors, which play a critical role in cell proliferation and differentiation. By fine-tuning this pathway, the company aims to restore normal tissue function in conditions characterized by inadequate healing or degeneration. Surrozen’s technology platform integrates advanced molecular engineering with novel screening approaches to generate multispecific antibodies that can precisely control Wnt receptor interactions. This platform has enabled the company to progress multiple preclinical candidates into the clinic, highlighting its commitment to innovative biologics discovery and translational research. Led by CEO David Hall, Surrozen operates with a management team that brings expertise in antibody engineering, translational biology, and clinical development. While based in the San Francisco Bay Area, the company collaborates with academic institutions and strategic partners globally to support its research efforts and accelerate the development of potential therapies for patients worldwide.Written by Jeffrey Neal JohnsonView Surrozen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong Upcoming Earnings Cintas (7/17/2025)Interactive Brokers Group (7/17/2025)Netflix (7/17/2025)PepsiCo (7/17/2025)Abbott Laboratories (7/17/2025)Elevance Health (7/17/2025)GE Aerospace (7/17/2025)American Noble Gas (7/17/2025)Marsh & McLennan Companies (7/17/2025)Novartis (7/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
